UA108277C2 - Complex preparation containing lercanidipine hydrochloride and valsartan, and method for production - Google Patents
Complex preparation containing lercanidipine hydrochloride and valsartan, and method for productionInfo
- Publication number
- UA108277C2 UA108277C2 UAA201307936A UAA201307936A UA108277C2 UA 108277 C2 UA108277 C2 UA 108277C2 UA A201307936 A UAA201307936 A UA A201307936A UA A201307936 A UAA201307936 A UA A201307936A UA 108277 C2 UA108277 C2 UA 108277C2
- Authority
- UA
- Ukraine
- Prior art keywords
- valsartan
- lercanidipine hydrochloride
- production
- preparation containing
- complex preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and a method for the preparation thereof. The pharmaceutical composition comprising lercanidipine hydro-chloride and valsartan according to the present invention has a superior effect on the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces the adverse effects of each component. In addition, the present composition comprises lercanidipine hydrochloride and valsartan in a separated form so as to increase the dissolution rates of both components and reduce the adverse effects.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100125804 | 2010-12-09 | ||
PCT/KR2011/009413 WO2012077968A2 (en) | 2010-12-09 | 2011-12-07 | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
UA108277C2 true UA108277C2 (en) | 2015-04-10 |
Family
ID=46207595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201307936A UA108277C2 (en) | 2010-12-09 | 2011-12-07 | Complex preparation containing lercanidipine hydrochloride and valsartan, and method for production |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP2648730A4 (en) |
KR (1) | KR101414814B1 (en) |
CN (1) | CN103249415B (en) |
AR (1) | AR084195A1 (en) |
AU (1) | AU2011339150B2 (en) |
BR (1) | BR112013013415A2 (en) |
CL (1) | CL2013001626A1 (en) |
CO (1) | CO6721030A2 (en) |
DO (1) | DOP2013000115A (en) |
EA (1) | EA201390844A1 (en) |
IL (1) | IL226449A0 (en) |
MX (1) | MX2013005716A (en) |
PE (1) | PE20140699A1 (en) |
SG (1) | SG190326A1 (en) |
UA (1) | UA108277C2 (en) |
UY (1) | UY33772A (en) |
WO (1) | WO2012077968A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102755322B (en) * | 2012-07-24 | 2013-12-11 | 兆科药业(广州)有限公司 | Compound preparation of lercanidipine and atorvastatin |
US20160045497A1 (en) * | 2013-03-12 | 2016-02-18 | Lg Life Sciences Ltd. | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
WO2019008485A1 (en) | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | Fixed dose pharmaceutical composition of valsartan and sacubitril |
KR102233986B1 (en) * | 2019-06-25 | 2021-03-30 | 경남과학기술대학교 산학협력단 | Solid pharmaceutical composition comprising lafutidine and irsogladin and process for producing thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
EP1694305B1 (en) * | 2003-12-01 | 2019-10-16 | Recordati Ireland Limited | Pharmaceutical compositions comprising lercanidipine |
WO2007001067A2 (en) | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker |
KR100888131B1 (en) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | Combination preparation for Cardiovascular disease therapy by Chronotherapy theory. |
-
2011
- 2011-12-06 UY UY0001033772A patent/UY33772A/en not_active Application Discontinuation
- 2011-12-07 AR ARP110104583A patent/AR084195A1/en unknown
- 2011-12-07 BR BR112013013415A patent/BR112013013415A2/en not_active IP Right Cessation
- 2011-12-07 MX MX2013005716A patent/MX2013005716A/en unknown
- 2011-12-07 EA EA201390844A patent/EA201390844A1/en unknown
- 2011-12-07 CN CN201180058951.9A patent/CN103249415B/en active Active
- 2011-12-07 UA UAA201307936A patent/UA108277C2/en unknown
- 2011-12-07 WO PCT/KR2011/009413 patent/WO2012077968A2/en active Application Filing
- 2011-12-07 AU AU2011339150A patent/AU2011339150B2/en not_active Ceased
- 2011-12-07 SG SG2013038211A patent/SG190326A1/en unknown
- 2011-12-07 KR KR1020110130400A patent/KR101414814B1/en active IP Right Grant
- 2011-12-07 PE PE2013001346A patent/PE20140699A1/en not_active Application Discontinuation
- 2011-12-07 EP EP11847739.7A patent/EP2648730A4/en not_active Withdrawn
-
2013
- 2013-05-20 IL IL226449A patent/IL226449A0/en unknown
- 2013-05-21 DO DO2013000115A patent/DOP2013000115A/en unknown
- 2013-06-06 CL CL2013001626A patent/CL2013001626A1/en unknown
- 2013-06-21 CO CO13147794A patent/CO6721030A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20120089787A (en) | 2012-08-13 |
MX2013005716A (en) | 2013-06-12 |
AU2011339150B2 (en) | 2015-09-10 |
DOP2013000115A (en) | 2014-07-31 |
BR112013013415A2 (en) | 2019-09-24 |
EP2648730A4 (en) | 2014-08-06 |
UY33772A (en) | 2012-07-31 |
CN103249415B (en) | 2017-12-12 |
PE20140699A1 (en) | 2014-06-13 |
EA201390844A1 (en) | 2013-11-29 |
SG190326A1 (en) | 2013-06-28 |
EP2648730A2 (en) | 2013-10-16 |
IL226449A0 (en) | 2013-07-31 |
CO6721030A2 (en) | 2013-07-31 |
WO2012077968A2 (en) | 2012-06-14 |
CL2013001626A1 (en) | 2013-10-04 |
KR101414814B1 (en) | 2014-07-21 |
CN103249415A (en) | 2013-08-14 |
AU2011339150A1 (en) | 2013-06-06 |
WO2012077968A3 (en) | 2012-07-26 |
AR084195A1 (en) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY173823A (en) | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same | |
IN2012DN03312A (en) | ||
IN2014KN00948A (en) | ||
MY156777A (en) | Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof | |
IL219437A (en) | Substituted benzamide derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of a medicament for treating cardiovascular disorders | |
WO2010092090A3 (en) | Novel salts of sitagliptin | |
MX360554B (en) | Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2. | |
WO2011157722A3 (en) | Solid ivabradine-containing composition | |
PH12015500653A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
WO2014203275A3 (en) | An improved process for the preparation of apixaban and intermediates thereof | |
WO2012162439A3 (en) | Compositions comprising fusidic acid and packages therefor | |
ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
UA108277C2 (en) | Complex preparation containing lercanidipine hydrochloride and valsartan, and method for production | |
PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
WO2012155226A8 (en) | Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof | |
MX2013002261A (en) | Substituted n-phenethyltriazoloneacetamides and use thereof. | |
PH12014502836B1 (en) | Medicament form for release of active ingredients | |
MX2013011884A (en) | Modified release pharmaceutical compositions of desvenlafaxine. | |
WO2013124832A3 (en) | Stabilized controlled-release pharmaceutical composition comprising gliclazide | |
WO2013054364A3 (en) | Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof | |
TN2013000212A1 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof | |
WO2012114352A3 (en) | Pharmaceutical compositions of maraviroc and process for the preparation thereof | |
WO2011139255A3 (en) | Pharmaceutical compositions comprising cefetamet | |
WO2012131412A3 (en) | Pharmaceutical composition containing no, process for the preparation and use thereof | |
WO2011121475A3 (en) | Modified release dosage form comprising desvenlafaxine or salts thereof |